Bionic Boy wrote:
"The last analyst report over a year old now put the valuation per share at 40 cents and a lot has happened since then.
http://www.neurenpharma.com/ssl/cms/files_cms/200807%20TC%20Glypromate.pdf"
A lot has happened since that analyst report was released, including the failure of Phase III of the Glypromate Trial, and the blood letting as shareholders - including the Director threw stock away.
Like most biotechs NEU is highly volatile, buyer beware, don't invest more than you can afford to lose.
Still well underwater on this one. Good-luck to all.
M2
Bionic Boy wrote:"The last analyst report over a year old now...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |